ATHIRA PHARMA INC (ATHA) Stock News

USA - NASDAQ:ATHA - US04746L1044 - Common Stock

3.62 USD

-0.04 (-1.09%)

Last: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATHA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Athira Pharma, Inc.

Athira Pharma Announces Reverse Stock Split

a month ago - By: Athira Pharma, Inc.

Athira Pharma Announces Reverse Stock Split

2 months ago - By: Athira Pharma, Inc.

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

2 months ago - By: Athira Pharma, Inc.

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

2 months ago - By: The Motley Fool

Athira (ATHA) Q2 Loss Narrows 74%

a year ago - By: Benzinga - Mentions: OGEN ASST WISA FFIE ...

US Stocks Mixed; Trade Gap Widens In July

a year ago - By: BusinessInsider

News Image

ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024

2 months ago - By: Athira Pharma, Inc.

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Benzinga - Mentions: SSY SRPT CUE PDSB ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 months ago - By: Yahoo Finance - Mentions: ASND UBS CNQ KO

Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term

a year ago - By: InvestorPlace

ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024

5 months ago - By: Athira Pharma, Inc.

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

5 months ago - By: Athira Pharma, Inc.

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

5 months ago - By: Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

5 months ago - By: Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

8 months ago - By: Athira Pharma, Inc.

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

8 months ago - By: Athira Pharma, Inc.

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

11 months ago - By: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

11 months ago - By: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

a year ago - By: Athira Pharma, Inc.

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

a year ago - By: Athira Pharma, Inc.

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

a year ago - By: Athira Pharma, Inc.

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

a year ago - By: Athira Pharma, Inc.

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

a year ago - By: Yahoo Finance

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

a year ago - By: Athira Pharma, Inc.

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

a year ago - By: Athira Pharma, Inc.

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

a year ago - By: Athira Pharma, Inc.

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

a year ago - By: Athira Pharma, Inc.

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

a year ago - By: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024